Free Trial
→ Musk’s Project Colossus could mint millionaires (From Brownstone Research) (Ad) Buy RNA Stock  Free RNA Stock Alerts

Avidity Biosciences (RNA) Financials

Avidity Biosciences logo
$31.70 +0.80 (+2.59%)
Closing price 04:00 PM Eastern
Extended Trading
$31.70 +0.00 (+0.02%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Avidity Biosciences

Annual Income Statements for Avidity Biosciences

This table shows Avidity Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Net Income / (Loss) Attributable to Common Shareholders		 -322 -212 -174 -118 -44 -25 -11
Consolidated Net Income / (Loss)		 -322 -212 -174 -118 -44 -25 -11
Net Income / (Loss) Continuing Operations		 -322 -212 -174 -118 -44 -25 -11
Total Pre-Tax Income 		-322 -212 -174 -118 -44 -25 -10
Total Operating Income		 -379 -236 -179 -118 -44 -17 -10
Total Gross Profit		 11 9.56 9.22 9.33 6.79 2.32 0.38
Total Revenue		 11 9.56 9.22 9.33 6.79 2.32 0.38
Operating Revenue		 11 9.56 9.22 9.33 6.79 2.32 0.38
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 390 245 188 127 51 20 11
Selling, General & Admin Expense		 86 54 38 26 13 5.11 2.44
Research & Development Expense		 304 191 150 101 38 15 8.44
Total Other Income / (Expense), net		 57 23 4.92 0.04 -0.08 -7.40 0.00
Interest & Investment Income		 57 24 4.98 0.10 0.21 0.00 0.00
Other Income / (Expense), net		 -0.25 -0.59 -0.06 -0.06 -0.08 -0.02 0.00
Basic Earnings per Share		 ($2.89) ($2.91) ($3.34) ($2.85) ($2.05) ($9.12) ($4.53)
Weighted Average Basic Shares Outstanding		 111.58M 73.01M 52.16M 41.43M 21.66M 2.71M 2.48M
Diluted Earnings per Share		 ($2.89) ($2.91) ($3.34) ($2.85) ($2.05) ($9.12) ($4.53)
Weighted Average Diluted Shares Outstanding		 111.58M 73.01M 52.16M 41.43M 21.66M 2.71M 2.48M
Weighted Average Basic & Diluted Shares Outstanding		 120.21M 79.72M 70.81M 41.43M 21.66M 2.71M 2.48M

Quarterly Income Statements for Avidity Biosciences

This table shows Avidity Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -116 -102 -80 -71 -69 -60 -52 -47 -52 -50 -44
Consolidated Net Income / (Loss)		 -116 -102 -80 -71 -69 -60 -52 -47 -52 -50 -44
Net Income / (Loss) Continuing Operations		 -116 -102 -80 -71 -69 -60 -52 -47 -52 -51 -44
Total Pre-Tax Income 		-116 -102 -80 -71 -69 -60 -52 -47 -52 -50 -44
Total Operating Income		 -132 -121 -98 -83 -77 -67 -59 -53 -58 -53 -45
Total Gross Profit		 1.57 2.97 2.34 2.05 3.54 2.19 2.82 2.32 2.23 2.77 2.48
Total Revenue		 1.57 2.97 2.34 2.05 3.54 2.19 2.82 2.32 2.23 2.77 2.48
Operating Revenue		 1.57 2.97 2.34 2.05 3.54 2.19 2.82 2.32 2.23 2.77 2.48
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 133 124 100 85 81 69 61 55 60 56 47
Selling, General & Admin Expense		 34 28 23 21 14 16 14 12 12 10 10
Research & Development Expense		 99 96 77 64 67 53 48 43 48 46 37
Total Other Income / (Expense), net		 16 19 18 12 8.33 6.30 6.27 5.61 5.20 2.75 1.33
Interest & Investment Income		 16 19 18 12 8.43 6.41 6.28 5.77 5.52 2.77 1.34
Other Income / (Expense), net		 -0.44 0.20 -0.23 -0.12 -0.10 -0.11 -0.01 -0.16 -0.31 -0.02 -0.01
Basic Earnings per Share		 ($0.90) ($0.80) ($0.65) ($0.65) ($0.79) ($0.80) ($0.71) ($0.66) ($0.74) ($0.89) ($0.82)
Weighted Average Basic Shares Outstanding		 129.23M 111.58M 123.38M 106.93M 87.21M 73.01M 74.10M 71.39M 70.43M 52.16M 53.07M
Diluted Earnings per Share		 ($0.90) ($0.80) ($0.65) ($0.65) ($0.79) ($0.80) ($0.71) ($0.66) ($0.74) ($0.89) ($0.82)
Weighted Average Diluted Shares Outstanding		 129.23M 111.58M 123.38M 106.93M 87.21M 73.01M 74.10M 71.39M 70.43M 52.16M 53.07M
Weighted Average Basic & Diluted Shares Outstanding		 120.54M 120.21M 119.31M 109.80M 95.64M 79.72M 74.10M 74.10M 70.82M 70.81M 54.46M

Annual Cash Flow Statements for Avidity Biosciences

This table details how cash moves in and out of Avidity Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Net Change in Cash & Equivalents		 37 -155 20 -1.01 227 91 -4.56
Net Cash From Operating Activities		 -301 -119 -136 -95 -37 2.49 -9.66
Net Cash From Continuing Operating Activities		 -301 -119 -136 -95 -37 2.49 -9.66
Net Income / (Loss) Continuing Operations		 -322 -212 -174 -118 -44 -25 -11
Consolidated Net Income / (Loss)		 -322 -212 -174 -118 -44 -25 -11
Depreciation Expense		 2.78 2.10 1.39 0.64 0.37 0.35 0.38
Amortization Expense		 -21 -11 -0.62 0.18 0.01 0.07 0.07
Non-Cash Adjustments To Reconcile Net Income		 55 41 30 18 4.60 7.45 0.43
Changes in Operating Assets and Liabilities, net		 -15 61 7.07 4.63 2.26 19 0.65
Net Cash From Investing Activities		 -854 -130 -190 -83 -7.79 -0.24 -0.05
Net Cash From Continuing Investing Activities		 -854 -130 -190 -83 -7.79 -0.24 -0.05
Purchase of Property, Plant & Equipment		 -7.07 -4.23 -2.82 -3.74 -1.09 -0.24 -0.05
Purchase of Investments		 -1,434 -461 -356 -85 -6.69 0.00 0.00
Sale and/or Maturity of Investments		 586 335 169 6.58 0.00 0.00 -
Net Cash From Financing Activities		 1,192 94 346 176 272 89 5.14
Net Cash From Continuing Financing Activities		 1,192 94 346 176 272 89 5.14
Issuance of Common Equity		 1,192 94 346 176 275 0.00 0.00

Quarterly Cash Flow Statements for Avidity Biosciences

This table details how cash moves in and out of Avidity Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 34 -150 -206 107 286 99 -68 35 -222 197 19
Net Cash From Operating Activities		 -125 -100 -66 -65 -70 17 -37 -50 -49 -39 -32
Net Cash From Continuing Operating Activities		 -125 -100 -66 -65 -70 17 -37 -50 -49 -39 -32
Net Income / (Loss) Continuing Operations		 -116 -102 -80 -71 -69 -60 -52 -47 -52 -50 -44
Consolidated Net Income / (Loss)		 -116 -102 -80 -71 -69 -60 -52 -47 -52 -50 -44
Depreciation Expense		 0.79 0.74 0.71 0.69 0.64 0.62 0.57 0.53 0.39 0.38 0.37
Amortization Expense		 -5.16 -7.17 -6.85 -4.48 -2.96 -3.24 -2.97 -2.84 -2.23 -0.80 -0.04
Non-Cash Adjustments To Reconcile Net Income		 19 15 15 14 11 11 11 10 9.79 7.99 7.78
Changes in Operating Assets and Liabilities, net		 -23 -6.16 6.01 -4.06 -10 69 7.41 -11 -4.53 3.71 3.53
Net Cash From Investing Activities		 157 -64 -482 -275 -33 51 -31 46 -196 -7.77 11
Net Cash From Continuing Investing Activities		 157 -64 -482 -275 -33 51 -31 46 -196 -7.77 11
Purchase of Property, Plant & Equipment		 -3.75 -3.92 -1.70 -0.53 -0.92 -0.86 -0.92 -0.62 -1.82 -0.85 0.11
Purchase of Investments		 -169 -297 -622 -373 -142 -54 -132 -24 -251 -90 -54
Sale and/or Maturity of Investments		 330 237 142 98 110 106 101 71 57 83 64
Net Cash From Financing Activities		 1.94 14 342 447 389 32 0.04 39 23 244 40
Net Cash From Continuing Financing Activities		 1.94 14 342 447 389 32 0.04 39 23 244 40
Issuance of Common Equity		 1.94 14 342 447 389 32 0.04 39 23 244 40
Effect of Exchange Rate Changes		 0.04 - - - - - - - - - -

Annual Balance Sheets for Avidity Biosciences

This table presents Avidity Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Total Assets		 1,564 629 639 428 334 97
Total Current Assets		 1,542 611 623 411 332 96
Cash & Equivalents		 220 185 340 320 321 95
Short-Term Investments		 1,282 410 270 85 6.68 0.00
Prepaid Expenses		 41 16 12 5.60 3.54 1.10
Plant, Property, & Equipment, net		 13 8.38 6.25 4.81 1.47 0.63
Total Noncurrent Assets		 8.94 8.87 9.60 12 0.30 0.60
Other Noncurrent Operating Assets		 8.94 8.87 9.60 12 0.30 0.60
Total Liabilities & Shareholders' Equity		 1,564 629 639 428 334 97
Total Liabilities		 139 128 61 46 28 28
Total Current Liabilities		 98 81 52 30 15 10
Accounts Payable		 70 34 33 14 7.75 2.31
Current Deferred Revenue		 21 28 5.04 4.86 3.69 3.84
Current Employee Benefit Liabilities		 3.66 14 11 8.94 3.15 1.31
Other Current Liabilities		 3.84 3.64 3.11 1.77 - -
Total Noncurrent Liabilities		 41 47 8.82 16 13 17
Noncurrent Deferred Revenue		 38 41 1.24 6.53 12 15
Other Noncurrent Operating Liabilities		 2.96 6.21 7.58 9.96 0.94 0.44
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,425 501 578 381 306 -65
Total Preferred & Common Equity		 1,425 501 578 381 306 -65
Total Common Equity		 1,425 501 578 381 306 -65
Common Stock		 2,315 1,071 939 566 373 -43
Retained Earnings		 -893 -571 -359 -185 -67 -22
Accumulated Other Comprehensive Income / (Loss)		 2.90 0.13 -2.70 -0.19 -0.01 0.00

Quarterly Balance Sheets for Avidity Biosciences

This table presents Avidity Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,459 1,641 1,347 951 573 611 614 431
Total Current Assets		 1,435 1,622 1,329 934 555 595 597 414
Cash & Equivalents		 254 370 576 471 86 154 119 144
Short-Term Investments		 1,126 1,218 723 444 457 423 468 262
Prepaid Expenses		 55 33 30 19 13 18 11 8.92
Plant, Property, & Equipment, net		 16 9.49 8.50 8.66 8.13 7.78 7.85 6.04
Total Noncurrent Assets		 8.46 9.41 10 8.35 9.55 8.47 8.98 9.79
Other Noncurrent Operating Assets		 8.46 9.41 10 8.35 9.55 8.47 8.98 9.79
Total Liabilities & Shareholders' Equity		 1,459 1,641 1,347 951 573 611 614 431
Total Liabilities		 130 137 126 121 56 52 55 54
Total Current Liabilities		 85 91 84 75 49 45 48 43
Accounts Payable		 54 50 41 37 32 32 34 26
Current Deferred Revenue		 14 20 27 26 1.97 3.81 5.06 5.45
Current Employee Benefit Liabilities		 13 18 13 7.80 11 6.53 6.01 7.75
Other Current Liabilities		 3.88 3.80 3.77 3.73 3.60 3.15 3.13 3.09
Total Noncurrent Liabilities		 45 46 42 46 6.98 6.36 6.98 11
Capital Lease Obligations		 2.09 - - 5.42 6.98 - - 8.19
Noncurrent Deferred Revenue		 43 42 38 40 0.00 0.00 0.00 2.71
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,329 1,503 1,221 831 517 559 559 377
Total Preferred & Common Equity		 1,329 1,503 1,221 831 517 559 559 377
Total Common Equity		 1,329 1,503 1,221 831 517 559 559 377
Common Stock		 2,335 2,287 1,932 1,471 1,030 1,020 971 689
Retained Earnings		 -1,009 -791 -710 -640 -510 -458 -411 -308
Accumulated Other Comprehensive Income / (Loss)		 2.77 7.10 -0.45 -0.46 -1.88 -2.67 -1.53 -3.46

Annual Metrics And Ratios for Avidity Biosciences

This table displays calculated financial ratios and metrics derived from Avidity Biosciences' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Growth Metrics		 - - - - - - -
Revenue Growth		 13.99% 3.64% -1.09% 37.41% 192.67% 511.87% 0.00%
EBITDA Growth		 -62.15% -37.69% -51.92% -166.76% -159.75% -68.57% 0.00%
EBIT Growth		 -60.54% -31.97% -51.52% -166.31% -155.68% -65.24% 0.00%
NOPAT Growth		 -60.84% -31.68% -51.56% -166.62% -155.46% -65.10% 0.00%
Net Income Growth		 -51.87% -21.97% -47.44% -166.06% -79.33% -120.52% 0.00%
EPS Growth		 0.69% 12.87% -17.19% -39.02% 77.52% -101.32% 0.00%
Operating Cash Flow Growth		 -152.70% 12.63% -43.72% -155.44% -1,590.64% 125.79% 0.00%
Free Cash Flow Firm Growth		 -175.10% 11.75% -44.26% -176.16% -443.06% 0.00% 0.00%
Invested Capital Growth		 19.08% -189.68% -35.41% -7.78% -8.23% 0.00% 0.00%
Revenue Q/Q Growth		 7.71% -5.68% 11.04% -3.02% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -16.98% -6.89% -9.43% -23.18% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 -16.58% -6.11% -8.91% -23.25% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 -16.71% -6.09% -8.94% -23.23% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 -14.91% -4.93% -7.36% -23.25% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 3.00% -1.83% -630.77% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -63.07% 31.87% -10.52% -16.09% -27.71% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 -76.84% 34.80% -3.75% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 10.18% -421.54% -58.26% -32.84% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -3,651.05% -2,566.58% -1,931.90% -1,257.72% -647.86% -729.97% -2,649.60%
Operating Margin		 -3,477.43% -2,464.41% -1,939.65% -1,265.83% -652.38% -747.39% -2,769.92%
EBIT Margin		 -3,479.71% -2,470.63% -1,940.26% -1,266.49% -653.48% -748.04% -2,769.92%
Profit (Net Income) Margin		 -2,957.71% -2,219.87% -1,886.33% -1,265.38% -653.53% -1,066.58% -2,959.37%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 106.84%
Interest Burden Percent		 85.00% 89.85% 97.22% 99.91% 100.01% 142.58% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -33.47% -39.34% -36.27% -34.32% -23.62% -35.66% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -34.59% -37.27% -33.57% -31.02% -20.59% -17.90% 0.00%
Return on Assets (ROA)		 -29.40% -33.49% -32.63% -30.99% -20.59% -25.52% 0.00%
Return on Common Equity (ROCE)		 -33.47% -39.34% -36.27% -34.32% -15.15% 33.60% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -22.62% -42.38% -30.10% -30.94% -14.48% 37.84% 0.00%
Net Operating Profit after Tax (NOPAT)		 -265 -165 -125 -83 -31 -12 -7.35
NOPAT Margin		 -2,434.20% -1,725.09% -1,357.75% -886.08% -456.67% -523.17% -1,938.94%
Net Nonoperating Expense Percent (NNEP)		 -5.44% -7.84% -9.60% -9.64% -6.38% -27.99% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -18.61% -32.93% -21.66% - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 791.41% 566.84% 409.07% 280.88% 198.35% 220.44% 644.06%
R&D to Revenue		 2,786.02% 1,997.57% 1,630.57% 1,084.95% 554.03% 626.95% 2,225.86%
Operating Expenses to Revenue		 3,577.43% 2,564.41% 2,039.65% 1,365.83% 752.38% 847.39% 2,869.92%
Earnings before Interest and Taxes (EBIT)		 -379 -236 -179 -118 -44 -17 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -398 -245 -178 -117 -44 -17 -10
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 2.43 1.34 2.09 2.92 3.13 0.00 0.00
Price to Tangible Book Value (P/TBV)		 2.43 1.34 2.09 2.92 3.13 0.00 0.00
Price to Revenue (P/Rev)		 318.39 70.15 131.02 119.53 141.11 64.68 395.78
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 180.60 7.87 64.81 76.05 92.76 83.95 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 78.19 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 22.80 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.07 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.03 0.00
Financial Leverage		 -1.09 -1.12 -1.06 -1.07 -1.11 -1.30 0.00
Leverage Ratio		 1.14 1.17 1.11 1.11 1.15 1.40 0.00
Compound Leverage Factor		 0.97 1.06 1.08 1.11 1.15 1.99 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 6.15% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 3.75% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 2.39% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 182.28% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% -88.43% 0.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.27 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 5.32 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.10 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.37 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 7.42 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.15 0.00
Altman Z-Score		 14.50 1.67 11.32 14.07 21.21 3.44 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 35.87% 194.22% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 15.73 7.58 12.00 13.86 22.74 9.35 0.00
Quick Ratio		 15.32 7.38 11.77 13.67 22.50 9.24 0.00
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 -283 -103 -117 -81 -29 8.54 0.00
Operating Cash Flow to CapEx		 -4,258.00% -2,816.08% -4,827.06% -2,535.11% -3,398.99% 1,059.57% -19,704.08%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -140.16 1.16 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -177.59 0.34 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -182.82 0.31 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.01 0.02 0.02 0.02 0.03 0.02 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.04 1.31 1.67 2.97 6.47 3.68 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -77 -95 -33 -24 -22 -21 0.00
Invested Capital Turnover		 -0.13 -0.15 -0.33 -0.40 -0.32 -0.22 0.00
Increase / (Decrease) in Invested Capital		 18 -62 -8.54 -1.74 -1.70 -21 0.00
Enterprise Value (EV)		 1,968 75 598 709 630 195 0.00
Market Capitalization		 3,470 671 1,209 1,115 958 150 150
Book Value per Share		 $11.94 $6.76 $10.61 $8.13 $8.16 ($24.09) $0.00
Tangible Book Value per Share		 $11.94 $6.76 $10.61 $8.13 $8.16 ($24.09) $0.00
Total Capital		 1,425 501 578 381 306 74 0.00
Total Debt		 0.00 0.00 0.00 0.00 0.00 4.54 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 1.77 0.00
Net Debt		 -1,501 -595 -611 -406 -328 -90 0.00
Capital Expenditures (CapEx)		 7.07 4.23 2.82 3.74 1.09 0.24 0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -57 -65 -40 -24 -11 -6.36 0.00
Debt-free Net Working Capital (DFNWC)		 1,444 531 571 381 317 88 0.00
Net Working Capital (NWC)		 1,444 531 571 381 317 85 0.00
Net Nonoperating Expense (NNE)		 57 47 49 35 13 13 3.87
Net Nonoperating Obligations (NNO)		 -1,501 -595 -611 -406 -329 -90 0.00
Total Depreciation and Amortization (D&A)		 -19 -9.17 0.77 0.82 0.38 0.42 0.46
Debt-free, Cash-free Net Working Capital to Revenue		 -525.14% -677.03% -430.32% -257.99% -162.81% -274.43% 0.00%
Debt-free Net Working Capital to Revenue		 13,253.85% 5,550.49% 6,190.74% 4,090.53% 4,672.03% 3,803.97% 0.00%
Net Working Capital to Revenue		 13,253.85% 5,550.49% 6,190.74% 4,090.53% 4,672.03% 3,684.35% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 ($2.89) ($2.91) ($3.34) ($2.85) ($2.05) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 111.58M 73.01M 52.16M 47.75M 37.58M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($2.89) ($2.91) ($3.34) ($2.85) ($2.05) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 111.58M 73.01M 52.16M 47.75M 37.58M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.85) ($2.05) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 120.21M 79.72M 70.81M 41.43M 21.66M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -265 -165 -125 -83 -31 -12 -7.35
Normalized NOPAT Margin		 -2,434.20% -1,725.09% -1,357.75% -886.08% -456.67% -523.17% -1,938.94%
Pre Tax Income Margin		 -2,957.71% -2,219.87% -1,886.33% -1,265.38% -653.53% -1,066.58% -2,769.92%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -212.21 -2.35 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -148.30 -1.64 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -217.44 -2.38 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -153.52 -1.67 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.43% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.43% 0.00%

Quarterly Metrics And Ratios for Avidity Biosciences

This table displays calculated financial ratios and metrics derived from Avidity Biosciences' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -55.60% 35.57% -17.10% -11.70% 58.67% -20.80% 13.54% 6.34% 24.40% 49.51% 14.75%
EBITDA Growth		 -71.25% -83.12% -71.21% -57.02% -33.23% -29.46% -36.83% -20.01% -75.70% -40.11% -53.35%
EBIT Growth		 -70.73% -80.69% -67.75% -56.72% -33.46% -25.55% -30.48% -14.03% -67.93% -37.94% -53.46%
NOPAT Growth		 -70.39% -81.28% -67.39% -56.98% -34.01% -25.40% -30.48% -13.68% -67.14% -38.08% -53.45%
Net Income Growth		 -68.14% -69.18% -53.55% -50.54% -31.42% -19.76% -20.09% -2.92% -53.04% -30.96% -48.93%
EPS Growth		 -13.92% 0.00% 8.45% 1.52% -6.76% 10.11% 13.41% 28.26% -4.23% -7.23% -20.59%
Operating Cash Flow Growth		 -77.36% -705.24% -78.35% -30.51% -43.73% 142.11% -15.12% -40.12% -65.57% -49.49% -53.78%
Free Cash Flow Firm Growth		 -6,478.50% -775.27% 96.29% 108.16% 94.57% 152.98% -50.27% -8.94% -39.66% -13.77% -24.22%
Invested Capital Growth		 38.33% 19.08% -369.86% -350.27% -190.50% -189.68% 12.10% -12.76% -28.19% -35.41% -13.66%
Revenue Q/Q Growth		 -47.09% 27.27% 14.23% -42.28% 61.56% -22.18% 21.68% 3.72% -19.36% 11.56% 13.96%
EBITDA Q/Q Growth		 -7.16% -21.74% -20.77% -8.70% -14.59% -13.81% -10.76% 7.77% -11.35% -20.29% 2.85%
EBIT Q/Q Growth		 -9.24% -22.79% -18.88% -7.06% -15.62% -14.00% -11.07% 8.83% -8.77% -18.47% 2.94%
NOPAT Q/Q Growth		 -8.70% -23.29% -18.77% -7.05% -15.65% -13.85% -11.38% 8.62% -8.21% -18.46% 2.96%
Net Income Q/Q Growth		 -13.22% -27.19% -13.57% -2.81% -13.92% -15.44% -11.34% 10.25% -3.81% -15.76% 4.58%
EPS Q/Q Growth		 -12.50% -23.08% 0.00% 17.72% 1.25% -12.68% -7.58% 10.81% 16.85% -8.54% 10.87%
Operating Cash Flow Q/Q Growth		 -24.99% -52.21% -0.94% 7.64% -526.52% 144.85% 26.13% -1.72% -24.95% -22.62% 10.09%
Free Cash Flow Firm Q/Q Growth		 -19.28% -6,254.61% -156.79% 252.82% -112.24% 134.95% -24.80% -1.72% -19.42% 0.87% 9.53%
Invested Capital Q/Q Growth		 35.90% 10.18% -9.23% 1.94% 15.89% -421.54% -4.68% 36.74% 16.13% -58.26% -34.28%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -8,666.50% -4,279.04% -4,473.54% -4,231.30% -2,246.88% -3,167.81% -2,166.00% -2,379.40% -2,675.77% -1,937.92% -1,797.34%
Operating Margin		 -8,360.90% -4,069.59% -4,200.94% -4,040.39% -2,178.58% -3,043.46% -2,080.38% -2,272.63% -2,579.31% -1,922.17% -1,810.19%
EBIT Margin		 -8,388.56% -4,062.83% -4,210.87% -4,046.06% -2,181.43% -3,048.24% -2,080.84% -2,279.62% -2,593.37% -1,922.82% -1,810.68%
Profit (Net Income) Margin		 -7,360.01% -3,439.49% -3,441.70% -3,461.76% -1,943.41% -2,756.18% -1,857.98% -2,030.44% -2,346.35% -1,822.72% -1,756.61%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 87.74% 84.66% 81.73% 85.56% 89.09% 90.42% 89.29% 89.07% 90.47% 94.79% 97.01%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -34.19% -33.47% -27.76% -28.36% -32.91% -39.34% -45.22% -41.45% -41.12% -36.27% -41.99%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -62.13% -40.39% -38.48% -43.80% -30.29% -45.99% -42.03% -43.31% -48.41% -33.26% -35.12%
Return on Assets (ROA)		 -54.51% -34.19% -31.46% -37.47% -26.99% -41.58% -37.53% -38.58% -43.80% -31.53% -34.08%
Return on Common Equity (ROCE)		 -34.19% -33.47% -27.76% -28.36% -32.91% -39.34% -45.22% -41.45% -41.12% -36.27% -41.99%
Return on Equity Simple (ROE_SIMPLE)		 -27.79% 0.00% -18.66% -20.68% -27.52% 0.00% -39.08% -34.60% -34.38% 0.00% -42.99%
Net Operating Profit after Tax (NOPAT)		 -92 -85 -69 -58 -54 -47 -41 -37 -40 -37 -31
NOPAT Margin		 -5,852.63% -2,848.72% -2,940.66% -2,828.27% -1,525.00% -2,130.42% -1,456.26% -1,590.84% -1,805.52% -1,345.52% -1,267.14%
Net Nonoperating Expense Percent (NNEP)		 -2.07% -1.68% -1.10% -1.38% -1.98% -2.28% -2.43% -2.11% -2.46% -2.60% -3.00%
Return On Investment Capital (ROIC_SIMPLE)		 -6.92% -5.94% - - - -9.33% - - - -6.45% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 2,136.05% 953.18% 996.28% 1,013.74% 392.27% 735.02% 487.19% 530.14% 540.26% 375.01% 406.69%
R&D to Revenue		 6,324.86% 3,216.41% 3,304.67% 3,126.65% 1,886.31% 2,408.44% 1,693.19% 1,842.49% 2,139.05% 1,647.17% 1,503.51%
Operating Expenses to Revenue		 8,460.90% 4,169.59% 4,300.94% 4,140.39% 2,278.58% 3,143.46% 2,180.38% 2,372.63% 2,679.31% 2,022.17% 1,910.19%
Earnings before Interest and Taxes (EBIT)		 -132 -121 -98 -83 -77 -67 -59 -53 -58 -53 -45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -136 -127 -105 -87 -80 -69 -61 -55 -60 -54 -45
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.67 2.43 3.35 3.20 2.28 1.34 0.91 1.40 1.94 2.09 2.26
Price to Tangible Book Value (P/TBV)		 2.67 2.43 3.35 3.20 2.28 1.34 0.91 1.40 1.94 2.09 2.26
Price to Revenue (P/Rev)		 397.52 318.39 498.49 368.60 173.97 70.15 46.64 80.14 112.49 131.02 102.47
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 243.18 180.60 341.46 246.03 90.21 7.87 0.00 21.31 51.81 64.81 54.61
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.02
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.02
Financial Leverage		 -1.06 -1.09 -1.05 -1.05 -1.08 -1.12 -1.04 -1.04 -1.05 -1.06 -1.05
Leverage Ratio		 1.12 1.14 1.10 1.10 1.13 1.17 1.12 1.11 1.11 1.11 1.11
Compound Leverage Factor		 0.98 0.96 0.90 0.94 1.00 1.06 1.00 0.98 1.00 1.05 1.08
Debt to Total Capital		 0.16% 0.00% 0.00% 0.00% 0.65% 0.00% 1.33% 0.00% 0.00% 0.00% 2.13%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.16% 0.00% 0.00% 0.00% 0.65% 0.00% 1.33% 0.00% 0.00% 0.00% 2.13%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.84% 100.00% 100.00% 100.00% 99.35% 100.00% 98.67% 100.00% 100.00% 100.00% 97.87%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.02 0.00 -0.03 0.00 0.00 0.00 -0.05
Net Debt to EBITDA		 3.03 0.00 0.00 0.00 3.43 0.00 2.33 0.00 0.00 0.00 2.44
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.02 0.00 -0.03 0.00 0.00 0.00 -0.05
Debt to NOPAT		 -0.01 0.00 0.00 0.00 -0.03 0.00 -0.04 0.00 0.00 0.00 -0.07
Net Debt to NOPAT		 4.54 0.00 0.00 0.00 5.10 0.00 3.45 0.00 0.00 0.00 3.46
Long-Term Debt to NOPAT		 -0.01 0.00 0.00 0.00 -0.03 0.00 -0.04 0.00 0.00 0.00 -0.07
Altman Z-Score		 16.18 15.04 22.28 18.72 9.30 2.55 4.59 8.89 11.68 11.97 9.25
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 16.91 15.73 17.76 15.78 12.47 7.58 11.40 13.14 12.42 12.00 9.71
Quick Ratio		 16.26 15.32 17.39 15.43 12.22 7.38 11.14 12.74 12.19 11.77 9.51
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -123 -103 -1.62 2.85 -1.86 15 -44 -35 -34 -29 -29
Operating Cash Flow to CapEx		 -3,326.11% -2,550.33% -3,850.65% -12,241.81% -7,691.80% 1,912.05% -3,986.02% -8,007.56% -2,690.49% -4,610.47% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.74 1.04 1.15 1.30 1.32 1.31 1.43 1.41 1.50 1.67 1.79
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -49 -77 -85 -78 -80 -95 -18 -17 -27 -33 -21
Invested Capital Turnover		 -0.14 -0.13 -0.20 -0.22 -0.20 -0.15 -0.52 -0.60 -0.40 -0.33 -0.43
Increase / (Decrease) in Invested Capital		 30 18 -67 -61 -52 -62 2.50 -1.96 -6.02 -8.54 -2.48
Enterprise Value (EV)		 2,171 1,968 3,455 2,608 981 75 -63 209 501 598 454
Market Capitalization		 3,549 3,470 5,043 3,907 1,891 671 473 785 1,087 1,209 851
Book Value per Share		 $11.05 $11.94 $13.69 $12.77 $9.53 $6.76 $6.98 $7.90 $7.89 $10.61 $7.23
Tangible Book Value per Share		 $11.05 $11.94 $13.69 $12.77 $9.53 $6.76 $6.98 $7.90 $7.89 $10.61 $7.23
Total Capital		 1,331 1,425 1,503 1,221 836 501 524 559 559 578 385
Total Debt		 2.09 0.00 0.00 0.00 5.42 0.00 6.98 0.00 0.00 0.00 8.19
Total Long-Term Debt		 2.09 0.00 0.00 0.00 5.42 0.00 6.98 0.00 0.00 0.00 8.19
Net Debt		 -1,378 -1,501 -1,589 -1,299 -910 -595 -536 -577 -586 -611 -398
Capital Expenditures (CapEx)		 3.75 3.92 1.70 0.53 0.92 0.86 0.92 0.62 1.82 0.85 -0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -30 -57 -58 -54 -56 -65 -36 -27 -37 -40 -34
Debt-free Net Working Capital (DFNWC)		 1,350 1,444 1,531 1,245 860 531 507 549 549 571 372
Net Working Capital (NWC)		 1,350 1,444 1,531 1,245 860 531 507 549 549 571 372
Net Nonoperating Expense (NNE)		 24 18 12 13 15 14 11 10 12 13 12
Net Nonoperating Obligations (NNO)		 -1,378 -1,501 -1,589 -1,299 -910 -595 -536 -577 -586 -611 -398
Total Depreciation and Amortization (D&A)		 -4.37 -6.43 -6.14 -3.79 -2.32 -2.62 -2.40 -2.31 -1.84 -0.42 0.33
Debt-free, Cash-free Net Working Capital to Revenue		 -333.45% -525.14% -573.89% -513.79% -518.44% -677.03% -353.31% -277.68% -385.41% -430.32% -409.31%
Debt-free Net Working Capital to Revenue		 15,123.89% 13,253.85% 15,128.33% 11,742.51% 7,907.26% 5,550.49% 4,999.71% 5,605.00% 5,682.70% 6,190.74% 4,475.72%
Net Working Capital to Revenue		 15,123.89% 13,253.85% 15,128.33% 11,742.51% 7,907.26% 5,550.49% 4,999.71% 5,605.00% 5,682.70% 6,190.74% 4,475.72%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.90) ($0.80) ($0.65) ($0.65) ($0.79) ($0.80) ($0.71) ($0.66) ($0.74) ($0.89) ($0.82)
Adjusted Weighted Average Basic Shares Outstanding		 129.23M 111.58M 123.38M 106.93M 87.21M 73.01M 74.10M 71.39M 70.43M 52.16M 53.07M
Adjusted Diluted Earnings per Share		 ($0.90) ($0.80) ($0.65) ($0.65) ($0.79) ($0.80) ($0.71) ($0.66) ($0.74) ($0.89) ($0.82)
Adjusted Weighted Average Diluted Shares Outstanding		 129.23M 111.58M 123.38M 106.93M 87.21M 73.01M 74.10M 71.39M 70.43M 52.16M 53.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 120.54M 120.21M 119.31M 109.80M 95.64M 79.72M 74.10M 74.10M 70.82M 70.81M 54.46M
Normalized Net Operating Profit after Tax (NOPAT)		 -92 -85 -69 -58 -54 -47 -41 -37 -40 -37 -31
Normalized NOPAT Margin		 -5,852.63% -2,848.72% -2,940.66% -2,828.27% -1,525.00% -2,130.42% -1,456.26% -1,590.84% -1,805.52% -1,345.52% -1,267.14%
Pre Tax Income Margin		 -7,360.01% -3,439.49% -3,441.70% -3,461.76% -1,943.41% -2,756.18% -1,857.98% -2,030.44% -2,346.35% -1,822.72% -1,756.61%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Avidity Biosciences' Financials

When does Avidity Biosciences's financial year end?

According to the most recent income statement we have on file, Avidity Biosciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Avidity Biosciences' net income changed over the last 6 years?

Avidity Biosciences' net income appears to be on an upward trend, with a most recent value of -$322.30 million in 2024, rising from -$11.22 million in 2018. The previous period was -$212.22 million in 2023. Check out Avidity Biosciences' forecast to explore projected trends and price targets.

What is Avidity Biosciences's operating income?
Avidity Biosciences's total operating income in 2024 was -$378.94 million, based on the following breakdown:
  • Total Gross Profit: $10.90 million
  • Total Operating Expenses: $389.83 million
How has Avidity Biosciences revenue changed over the last 6 years?

Over the last 6 years, Avidity Biosciences' total revenue changed from $379 thousand in 2018 to $10.90 million in 2024, a change of 2,775.2%.

How much debt does Avidity Biosciences have?

Avidity Biosciences' total liabilities were at $138.94 million at the end of 2024, a 8.7% increase from 2023, and a 404.4% increase since 2019.

How much cash does Avidity Biosciences have?

In the past 5 years, Avidity Biosciences' cash and equivalents has ranged from $94.58 million in 2019 to $340.40 million in 2022, and is currently $219.87 million as of their latest financial filing in 2024.

How has Avidity Biosciences' book value per share changed over the last 6 years?

Over the last 6 years, Avidity Biosciences' book value per share changed from 0.00 in 2018 to 11.94 in 2024, a change of 1,194.3%.


Related Companies

This page (NASDAQ:RNA) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
As Bitcoin supply vanishes, this Trump-aligned token could explode
Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...
Crypto 101 Media | Sponsored
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...
Brownstone Research | Sponsored